<DOC>
	<DOCNO>NCT01053962</DOCNO>
	<brief_summary>This Phase IIa , randomize , double-blind , placebo-controlled , 14-day repeat oral , dose range study determine safety , pharmacokinetics ( PK ) pharmacodynamics ( PD ) effect SP-304 patient chronic idiopathic constipation .</brief_summary>
	<brief_title>SP-304 Dose Ranging Study Patients With Chronic Idiopathic Constipation</brief_title>
	<detailed_description>This Phase IIa , randomize , double-blind , placebo-controlled , 14-day repeat oral , dose range study determine safety , PK PD effect SP-304 patient chronic idiopathic constipation . Subjects diagnose chronic idiopathic constipation ( CIC ) screen anticipated 4 cohort , yield 80 randomized subject enrollment . Three dose cohort plan ( 1.0 mg , 3.0mg , 9.0 mg 0.3 mg ) 20 subject per dose cohort [ randomization ratio 3:1 ( 15 receive SP-304:5 receive placebo ) ] . Subjects continue meet entry criterion complete pre-treatment bowel movement ( BM ) diary receive , double-blind , randomize fashion , SP-304 match placebo . It expect subject complete 14 day dose ( include make accurate BM diary entry 14 day treatment period ) . All subject receive least one dose SP-304 matching placebo consider evaluable safety endpoint . If subject receives least 5 dos per treatment week ( 1 dose per day 7 day ) complete BM diary entry 5 dose day correspond treatment week , he/she consider evaluable .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>Subject able understand willing sign Informed Consent Form ( ICF ) capable provide write authorization use disclosure protect health information per requirement 45 CFR 164.508 ( Health Insurance Portability Accountability Act [ HIPAA ] ) . Subject male nonpregnant , nonbreastfeeding female , 18 75 year age ( inclusive ) time first dose . Subject body mass index ( BMI ) 18 35 kg/m2 ( See Appendix A formula calculate BMI ) . Subject meet Rome III Diagnostic Criteria functional chronic idiopathic constipation ( Drossman , 2006 ) past 3 month symptom onset &gt; 6 month prior diagnosis . Subject report loose stool ( mushy ) watery stool ( BSFS score 6 7 ) absence laxative , enema , suppository prohibit medicine &gt; 25 % BMs 3 month prior Screening visit 14 day pretreatment period . Subjects meet Rome III criterion IBS : report abdominal pain discomfort &gt; 3 days/week last 3 month symptom onset &gt; 6 month prior diagnosis . a2 14day pretreatment bowel movement diary . Subject fail complete pretreatment bowel movement diary accurately completely pretreatment period prior Day 1 dosing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Chronic Idiopathic Constipation</keyword>
	<keyword>Constipation</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
</DOC>